An let-7 KRAS rs712 polymorphism increases hepatocellular carcinoma risk

Xiong, Dabo; Song, Ying; Xiong, Wei; Liang, Yaping

doi:10.4238/2015.october.29.24

Cited by 7 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also reports a relatively young average age of HCC patients in Senegal (44±13.4 years), especially in patients with BRAF mutations (41±12.2 years) and concomitant KRAS/BRAF mutations (34±11.1 years). It seems likely that KRAS and BRAF mutations appear very early in liver carcinogenesis, especially in chronic HBV patients, especially since the risk of having the BRAF or KRAS mutation was respectively multiplied by 2 (CI(95)=0.55-7.24; p=0.395) and by 1.78 (CI(95)=0.23-13.5; p=1) in these patients, as reported by Xiong et al [30].…”

Section: Discussionsupporting

confidence: 60%

KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal

Thiam¹,

Thorpe²,

Mawuli³

et al. 2022

IJGG

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a public health problem in developing countries where chronic HBV is endemic. The objective of our study was to determine the prevalence of KRAS and BRAF mutations in patients with HCC. Mutations in codons 12 and 13 of KRAS and the V600E mutation of the BRAF gene were searched by HRM on Light Cycler 480 and confirmed by direct sequencing. A total of 34 HCC patients underwent molecular testing for codon 12 and 13 mutations in the KRAS gene and the V600E mutation in the BRAF gene. Melting curve analysis showed a prevalence of 23.5% (n=8/34) for the KRAS gene and 41.2% (n=14/34) for the BRAF gene. The mean age of BRAF mutation carriers was lower compared with KRAS mutation carriers. Chronic HBV carriage appeared to play a role in the development of these mutations, increasing the risk by 2 (CI(95)=0. 55-7.24; p=0.395) for BRAF and by 1.78 (CI(95)=0.23-13.5; p=1) for KRAS. KRAS and BRAF mutations do not appear to play a role in tumor metastasis. However, these results need to be confirmed by further studies with a larger sample size. Alterations in the RAS/RAF/MAP Kinase pathway appear to be more prominent in HBV-induced HCC. This may hinder management with receptor tyrosine kinase inhibitors, the basis for treatment of advanced HCC.

show abstract

Section: Discussionsupporting

confidence: 60%

KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal

Thiam¹,

Thorpe²,

Mawuli³

et al. 2022

IJGG

View full text Add to dashboard Cite

show abstract

“…Xiong et al ( 65 ) studied the KRAS G/T SNP (rs712), a genetic variation with implications to the binding of miR-let-7 and miR-181. According to these authors, the TT genotype increases the risk of HBV-associated HCC.…”

Section: Viral Infections and Polymorphic Variants That Affect Mirnasmentioning

confidence: 99%

“…According to these authors, the TT genotype increases the risk of HBV-associated HCC. This influence occurs possibly by a modified expression of KRAS due to the rs712-induced changes in the miR-let-7-binding site ( 65 ). Li et al ( 66 ) explored the effect of five SNPs in miRNA-binding sites (located at RAD52 gene) on the risk of HBV-associated HCC.…”

Section: Viral Infections and Polymorphic Variants That Affect Mirnasmentioning

confidence: 99%

MicroRNA-Related Polymorphisms in Infectious Diseases—Tiny Changes With a Huge Impact on Viral Infections and Potential Clinical Applications

2018

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are single-stranded sequences of non-coding RNA with approximately 22 nucleotides that act posttranscriptionally on gene expression. miRNAs are important gene regulators in physiological contexts, but they also impact the pathogenesis of various diseases. The role of miRNAs in viral infections has been explored by different authors in both population-based as well as in functional studies. However, the effect of miRNA polymorphisms on the susceptibility to viral infections and on the clinical course of these diseases is still an emerging topic. Thus, this review will compile and organize the findings described in studies that evaluated the effects of genetic variations on miRNA genes and on their binding sites, in the context of human viral diseases. In addition to discussing the basic aspects of miRNAs biology, we will cover the studies that investigated miRNA polymorphisms in infections caused by hepatitis B virus, hepatitis C virus, human immunodeficiency virus, Epstein–Barr virus, and human papillomavirus. Finally, emerging topics concerning the importance of miRNA genetic variants will be presented, focusing on the context of viral infectious diseases.

show abstract

“…12 According to existing reports, the functional SNP of the miRNA let-7 binding site in the 3'UTR of KRAS mRNA may be related to the risk of various cancers, including colorectal cancer, lung nasopharyngeal cancer and ovarian cancer. [13][14][15][16][17] Therefore, studying the 3'UTR-related gene polymorphism of KRAS will have an essential role in the early diagnosis, treatment and prognosis of cancer.…”

Section: Introductionmentioning

confidence: 99%

“…The let‐7 microRNA (miRNA) family, as a small, non‐coding RNA molecule, has a vital role in the process of carcinogenesis by targeting tumour suppressor genes or as highly expressed oncogenes 12 . According to existing reports, the functional SNP of the miRNA let‐7 binding site in the 3'UTR of KRAS mRNA may be related to the risk of various cancers, including colorectal cancer, lung nasopharyngeal cancer and ovarian cancer 13–17 . Therefore, studying the 3'UTR‐related gene polymorphism of KRAS will have an essential role in the early diagnosis, treatment and prognosis of cancer.…”

Section: Introductionmentioning

confidence: 99%

Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population

Min

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective The KRAS gene has a pathophysiological role in the development of many cancers. This study aims to investigate the relationship between KRAS polymorphisms and genetic susceptibility to breast cancer. Method The rs712, rs12587 and rs9266 gene loci in the KRAS gene of 421 subjects (141 breast cancer patients, 141 benign breast tumours and 139 healthy controls) were analysed by the polymerase chain reaction and SNaPshot sequencing. Transcriptomic information on KRAS and corresponding clinical information was downloaded from the TCGA and GTEx databases. Differences in KRAS expression between breast cancer tissues and control tissues were analysed. Results We found no significant association between KRAS rs712 and rs12587 locus gene polymorphisms and an increased risk of developing benign breast tumours and breast cancer (p > 0.05). The KRAS rs9266 locus mutation heterozygous model CT and dominant model CT + TT were significantly associated with an increased risk of breast cancer (both p < 0.05). In addition, the TAT haplotype was expressed at an increased frequency, and the GAC haplotype was expressed at a reduced frequency in breast cancer compared with controls (both p < 0.05). We found that KRAS was over expressed in breast cancer tumour tissues compared with the control tissues (p < 0.0001). Conclusion The KRAS rs9266 gene polymorphism and the TAT haplotype may be associated with an increased risk of breast cancer in Chinese women. The GAC haplotype may be a protective factor against breast cancer.

show abstract

An let-7 KRAS rs712 polymorphism increases hepatocellular carcinoma risk

Cited by 7 publications

References 26 publications

KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal

KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal

MicroRNA-Related Polymorphisms in Infectious Diseases—Tiny Changes With a Huge Impact on Viral Infections and Potential Clinical Applications

Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population

Contact Info

Product

Resources

About